Importantly, Steeghs et al. (2017) demonstrated that the ex vivo efficacy of ruxolitinib in CRLF2r/JAK2-mutant primary ALL cells was highly dependent on the addition of human TSLP (Steeghs et al., 2017). The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.